TECX GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
AvroBio Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.
Current Price
$28.53
-1.69%Profile
Valuation (TTM)
Market Cap$543.15M
P/E-7.32
EV—
P/B2.16
Shares Out19.04M
P/Sales—
Revenue$0.00
EV/EBITDA—
AvroBio Inc (TECX) Quality Analysis
TECX Profitability
Profitability trend analysis coming soon
TECX Growth
Growth trend analysis coming soon
TECX Financial Health
Financial health indicators coming soon
TECX Quality & Fundamental Analysis
AvroBio Inc (TECX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates AvroBio Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
AvroBio Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. and a return on equity (ROE) of -29.50%. Return on assets (ROA) stands at -28.41%.
The debt-to-equity ratio is 0.01, with a current ratio of 26.63.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether AvroBio Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.